This opens doors for the development of vaccine candidates that can take on many SARS CoV-2 variants, and if the antibodies triggered by B.1.351 target the non-differentiated parts of the spike protein, then it could be a home run for the fighting all incarnations of SARS CoV-2.
from The Financial Express https://ift.tt/3w5H6MD
No comments:
Post a Comment